Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.
OvaCheck is a cutting-edge multivariate index assay that measures the relative ratios of eight proteins. It employs a bead-based multiplexed immunoassay platform and Correlogic's proprietary software system to return a result. The simple blood test will help physicians more accurately determine whether a pelvic mass is ovarian cancer -- leading to earlier, appropriate treatment and fewer unnecessary surgeries.
Ovarian cancer is the most deadly gynecologic cancer, in significant part because detection has been difficult and the disease is overwhelmingly detected when it is advanced. Europe has among the highest incidence rates of ovarian cancer in the world.
"Accurate detection of ovarian cancer has been elusive, but it is essential to saving lives," said Peter Levine, CEO of Correlogic. "OvaCheck can be a powerful tool for earlier, more accurate detection of ovarian cancer without an invasive procedure -- a real advancement in confronting this disease."
Correlogic is currently in discussions with potential partners for distribution of OvaCheck in Europe.
Breakthrough imaging method enhances precision in prostate cancer treatment